FDA grants priority review to Roche’s Lunsumio for Relapsed or Refractory Follicular Lymphoma
Approval is based on results from the pivotal phase-I/II clinical study of Lunsumio
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.